Business Context and Reporting Period
This Form 8-K is filed by TransBiotec, Inc. (not SOBR Safe, Inc., despite the metadata reference) for the reporting period ending December 2, 2019. The filing addresses corporate governance changes, specifically the appointment of two executive officers to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and equity compensation arrangements rather than financial performance.
Material Changes
- Board Appointments: On November 22, 2019, the Board approved the appointment of Kevin Moore (CEO) and David Gandini (CRO) as directors, effective December 2, 2019.
- Executive Compensation:
- Kevin Moore: Granted 35,200,000 incentive stock options at an exercise price of $0.00792 per share. Vesting occurs over 36 months.
- David Gandini: Granted 32,000,000 incentive stock options at an exercise price of $0.00792 per share. 24,000,000 options vest over 36 months; 8,000,000 "Pre-Vesting Option Shares" vest in two tranches (November 1, 2019, and January 1, 2020).
- Contingent Equity: Mr. Gandini is entitled to 1,000,000 shares of common stock upon the closing of the IDTEC Transaction, subject to a reverse stock split.
Outlook, Risks, and Management Commentary
The filing highlights the extensive business backgrounds of the new directors, including experience in heavy equipment, quality management, telecommunications, and manufacturing. No specific financial guidance, risk factors, or unusual items regarding the company's operational outlook are disclosed in this document.
Investor Verification Checklist
- Verify the correct registrant name is TransBiotec, Inc., not SOBR Safe, Inc.
- Confirm the total number of shares outstanding to assess the dilution impact of the 67.2 million options granted to Moore and Gandini.
- Review the status of the "IDTEC Transaction" to determine if the contingent 1,000,000 shares for Mr. Gandini will be issued.
- Check the company's 2019 Equity Compensation Plan to ensure sufficient shares were reserved for these grants.